Step 1 topics → Neurology and Special Senses → Guillain-Barré and Related Peripheral Demyelination

Guillain-Barré and Related Peripheral Demyelination

USMLE Step 1 trap: Confuses the ascending pattern of GBS with the descending paralysis of botulism. GBS causes ascending weakness starting in the distal lower extremities and progressing upward.

Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyneuropathy characterized by progressive ascending weakness, areflexia, and sensory disturbances — and the most dangerous misconception on USMLE Step 1 is reaching for corticosteroids as treatment because the disease is immune-mediated. Trials consistently show steroids don't help GBS and may worsen outcomes; IVIG and plasmapheresis are the correct first-line options. The most common subtype — AIDP (acute inflammatory demyelinating polyneuropathy) — results from molecular mimicry, most classically after Campylobacter jejuni infection, where antibodies against bacterial lipopolysaccharides cross-react with peripheral nerve myelin.

The exam tests GBS through clinical vignettes where you must identify the pattern of weakness, interpret CSF findings, and choose the correct treatment. The trickiest part is that students often rely on surface-level heuristics — 'immune-mediated disease = steroids' or 'paralysis = check if it's descending or ascending without knowing why' — and those heuristics fail here. The albuminocytologic dissociation on CSF (high protein, normal white cells) is a classic USMLE Step 1 data point that trips up students who expect inflammation to correlate with pleocytosis. Understanding why this pattern exists — demyelination without active intrathecal cellular inflammation — is what separates recall from actual understanding.

Respiratory compromise is the life-threatening complication you must flag immediately. Weakness ascending to the diaphragm requires serial FVC and NIF monitoring, not just clinical observation. On the management side, the steroid trap is real: because GBS is immune-mediated, students reflexively reach for corticosteroids — but trials consistently show steroids don't help and may worsen outcomes. IVIG and plasmapheresis are equivalent first-line options. Nail these distinctions and GBS becomes one of the more reliable high-yield topics on Step 1.

From real student decks
78%have cards covering this topic
54%have mature cards

Common misconceptions

Common mistake
Wrong: GBS causes descending paralysis like botulism.
Right: GBS causes ascending weakness starting in the distal lower extremities and progressing upward.
GBS produces ascending paralysis — weakness begins in the distal legs and travels upward toward the trunk and respiratory muscles. This is the opposite of botulism, which causes descending paralysis starting cranially. The distinction matters on the exam because both can cause flaccid paralysis and areflexia, but the direction of progression and the mechanism (peripheral demyelination vs. presynaptic ACh blockade) are completely different. When you see a vignette with leg weakness after a GI illness progressing upward, think GBS.
Common mistake
Wrong: Corticosteroids are a first-line treatment for GBS because it is immune-mediated.
Right: Steroids are not beneficial in GBS and may worsen outcomes; IVIG and plasmapheresis are the first-line treatments.
The 'immune-mediated = steroids' shortcut breaks down completely with GBS. Multiple randomized trials have shown that corticosteroids provide no benefit in GBS and may actually delay recovery or worsen outcomes. The correct first-line treatments are IVIG and plasmapheresis, which work by neutralizing pathogenic antibodies and removing them from circulation, respectively. Treating with steroids instead is a classic wrong answer on USMLE Step 1, designed specifically to punish pattern-matching over mechanistic reasoning.
Common mistake
Wrong: Students expect GBS CSF to show both elevated protein and elevated white cells.
Right: GBS CSF shows albuminocytologic dissociation: elevated protein with normal cell count.
In most CNS infections or inflammatory conditions, elevated protein in the CSF goes hand-in-hand with elevated white cells (pleocytosis). In GBS, however, the inflammation is happening in the peripheral nervous system — not inside the intrathecal space. Protein leaks into the CSF from damaged peripheral nerve roots, but there's no active cellular immune response within the spinal fluid itself, so the cell count stays normal. This pattern — high protein, normal cells — is the hallmark albuminocytologic dissociation, and recognizing it is a direct Step 1 test point.
Common mistake
Wrong: GBS (AIDP) targets the axon directly.
Right: AIDP targets peripheral nerve myelin via molecular mimicry, with T-cell and antibody-mediated attack on Schwann cells and myelin.
AIDP attacks the myelin sheath and Schwann cells of peripheral nerves, not the axons themselves. The distinction matters clinically: demyelinating injury is more reversible because axons can remyelinate, while axonal variants (AMAN, AMSAN) carry a worse prognosis. Molecular mimicry is the mechanism — antibodies generated against pathogens like C. jejuni cross-react with gangliosides or myelin antigens on peripheral nerves. If you see nerve conduction studies showing slowed conduction velocity and prolonged latencies (rather than reduced amplitude), that points to demyelination, consistent with AIDP.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Pathology: Know that AIDP targets peripheral nerve myelin (not axons directly) through molecular mimicry — T-cell and antibody-mediated attack on Schwann cells — and identify Campylobacter jejuni, EBV, CMV, and post-vaccination as classic triggers.
  2. Presentation: Recognize the ascending pattern of weakness starting in the distal lower extremities, accompanied by areflexia and autonomic dysfunction, and identify respiratory failure as the most dangerous complication requiring urgent monitoring.
  3. Diagnosis: Interpret CSF showing albuminocytologic dissociation (elevated protein with normal cell count), understand how nerve conduction studies demonstrate demyelination, and know that serial forced vital capacity (FVC) and NIF monitor respiratory status.
  4. Management: Identify IVIG and plasmapheresis as the two equivalent first-line treatments, and recognize that corticosteroids are NOT beneficial in GBS despite its immune-mediated mechanism.

Can you avoid these mistakes?

A 28-year-old man presents with 3 days of progressive bilateral leg weakness and difficulty walking, 2 weeks after recovering from bloody diarrhea. He has absent deep tendon reflexes. Lumbar puncture shows protein 95 mg/dL and 2 WBCs/mm³. What is the diagnosis, and what does the CSF pattern reflect?
A medical student argues that because GBS is caused by an autoimmune attack, the treatment should include high-dose corticosteroids. What is wrong with this reasoning, and what should you use instead?
You are monitoring a patient admitted for GBS. Which specific respiratory measurement best predicts the need for intubation, and at what threshold should you act?
How would you distinguish GBS from botulism in a clinical vignette — specifically, what features of the paralysis pattern, reflexes, and autonomic involvement would help you differentiate the two?

Related topics

Neural Tube Formation and Derivatives Neural Crest Derivatives Neural Tube Defects Other Developmental Malformations

See how your Anki deck covers this topic.

Upload your deck for a free audit →